CN Patent

CN101227909A — 包含嘧啶基氨基苯甲酰胺化合物和Flt-3抑制剂用于治疗增殖性疾病的组合

Assigned to Novartis AG · Expires 2008-07-23 · 18y expired

What this patent protects

本发明提供了包含下列物质的药物组合：a)嘧啶基氨基苯甲酰胺化合物；和b)Flt－3抑制剂，以及利用该组合治疗或预防增殖性疾病的方法。

USPTO Abstract

本发明提供了包含下列物质的药物组合：a)嘧啶基氨基苯甲酰胺化合物；和b)Flt－3抑制剂，以及利用该组合治疗或预防增殖性疾病的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN101227909A
Jurisdiction
CN
Classification
—
Expires
2008-07-23
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.